Monoclonal Antibody to Receptor Activator Of Nuclear Factor Kappa B (RANk)
| Code | Size | Price |
|---|
| MAC057Hu22-20ul | 20ul | £90.00 |
Quantity:
| MAC057Hu22-100ul | 100ul | £169.00 |
Quantity:
| MAC057Hu22-200ul | 200ul | £229.00 |
Quantity:
| MAC057Hu22-1ml | 1ml | £526.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CD265; TNFRSF11A; TNFRSF11-A; ODFR; OFE; TRANCER; Osteoclast differentiation factor receptor; Tumor Necrosis Factor Receptor Superfamily,Member 11a,NFKB Activator
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Receptor Activator Of Nuclear Factor Kappa B
Potency (Clone Number):
D13
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Receptor Activator Of Nuclear Factor Kappa B (RANk) | RPC057Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||